Dyskinesia News and Research

RSS

Increased signaling by sonic hedgehog protein can inhibit LID in Parkinson's patients

Levodopa, or L-dopa, is considered the most effective treatment for Parkinson's disease today. After a few years of treatment, however, almost all patients develop a debilitating side-effect called L-dopa induced dyskinesia, or LID, which causes involuntary movements in the limbs, face, and torso. Deep brain stimulation can alleviate LID, but the procedure is highly invasive and not all patients are eligible.

23 Sep 2021

Pioneering neural recordings lay the groundwork for personalized Parkinson's treatments

Pioneering neural recordings in patients with Parkinson's disease by UC San Francisco scientists lays the groundwork for personalized brain stimulation to treat Parkinson's and other neurological disorders.

4 May 2021

Researchers survey patients to find out which Parkinson's symptoms troubled the most

Individuals with Parkinson's disease (PD) face a wide range of symptoms and challenges. A team from Parkinson's UK, including several Patient and Public Involvement (PPI) contributors, surveyed patients to find out which PD symptoms troubled them most and how priorities may change with condition duration.

27 Apr 2021

New grants could help protect the environment and create new therapy for Parkinson's

New grants from the State University of New York could help researchers at Binghamton University create a new therapy to provide relief to Parkinson's patients and help locate abandoned oil and gas wells.

12 Apr 2021

Study reveals link between changes of neuronal activities and dyskinesia

Many people with Parkinson's disease develop abnormal movements called L-DOPA induced dyskinesia, a major side effect of long-term medication. The mechanism underlying this side effect has been unknown. In this study, researchers have revealed relation between changes of neuronal activities and dyskinesia.

9 Apr 2021

Defective metabolism of Parkinson’s drug is linked to adverse side effects

Until now, the reason why the drug levodopa (L-Dopa), which reduces the motor symptoms of Parkinson's disease, declines in efficacy after a few years' use has been unknown.

7 Jan 2021

NTU-incubated start-up plans clinical trial of new slow-release pill for Parkinson’s disease

Materials scientists from Nanyang Technological University, Singapore (NTU Singapore) have developed a new pill which uses the stomach as a drug reservoir and delivers medicines slowly over time to patients with Parkinson's disease (PD).

16 Sep 2020

Natural molecules that stimulate dopamine production may help reverse Parkinson's disease

Investigators have identified two molecules naturally produced by the body that stimulate the production of dopamine, the molecule that is in short supply in the brains of patients with Parkinson's disease.

4 Jun 2020

Research reveals mechanism underlying Parkinson's dyskinesia

Many people with Parkinson's disease eventually develop debilitating movements called dyskinesia, a side effect of their much-needed dopamine replacement medication.

3 May 2020

Experimental drug offers hope for improving movement symptoms of Parkinson's

Results from a study looking at an experimental drug to tackle the debilitating side effect of dyskinesia, have offered hope that it may have potential as a future treatment for people with Parkinson's.

2 Mar 2020

Medicinal cannabis substitute may help unlock new treatment for Parkinson's disease

A drug that provides the benefits obtained from medicinal cannabis without the "high" or other side effects may help to unlock a new treatment for Parkinson's disease.

19 Dec 2019

Research shows how cilia and exocyst contribute to extracellular vesicle production

Although the cilium has been known to scientists for more than 100 years, it is only recently that it has been acknowledged to play important roles in physiology.

25 Nov 2019

Novel clinical trial to examine use of cannabidiol in people with Parkinson's-related psychosis

A pioneering clinical trial will investigate the use of cannabidiol (CBD) - a compound found in the cannabis plant - in people with Parkinson's-related psychosis.

14 Oct 2019

Prilenia's lead compound selected to participate in first-ever ALS platform trial

Prilenia, a newly formed biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announces that Pridopidine, its lead compound, has been selected as the first of three potential new treatments to be included in the launch of the first ever platform trial in amyotrophic lateral sclerosis (ALS).

19 Sep 2019

Simple, minimally-invasive tool to study nasal airways of cystic fibrosis patients

A paper published today in Science Translational Medicine describes a simple, minimally invasive new tool for viewing differences in the nasal airways of cystic fibrosis patients in vivo at a cellular level.

8 Aug 2019

Study provides better understanding of how cilia work and what causes oscillations

Human bodies have some built-in systems to care for themselves. The cells that line our lungs, nose, brain and reproductive system have cilia, which are tiny, hair-like structures designed to sweep out fluids, cells and microbes to stay healthy.

30 Mar 2019

Study shows how gut bacteria affect the treatment of Parkinson's disease

Patients with Parkinson's disease are treated with levodopa, which is converted into dopamine, a neurotransmitter in the brain. In a study published on 18 January in the journal Nature Communications, scientists from the University of Groningen show that gut bacteria can metabolize levodopa into dopamine.

18 Jan 2019

Researchers identify link between mucus in the small airways and pulmonary fibrosis

A team of investigators led by members of the University of Colorado School of Medicine faculty at CU Anschutz Medical Campus has identified a connection between mucus in the small airways and pulmonary fibrosis.

18 Dec 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Babies exposed to higher levels of organochlorine compounds in womb may have worse lung function

Babies exposed to higher levels of organochlorine compounds in the womb go on to have worse lung function in childhood, according to new research presented today at the European Respiratory Society International Congress.

18 Sep 2018